Abstract
Palmar plantar erythrodysesthesia (PPE) is a distinctive and relatively frequent toxic reaction related to some chemotherapeutic agents. Doxorubicin, cytarabine, docetaxel, and fluorouracil are the most frequently implicated agents. PPE seems to be dose dependent and both peak drug concentration and total cumulative dose determine its occurrence.
PPE presents as a painful erythema, often preceded by paresthesia, located on the palms and soles in the context of treatment with chemotherapy. Histologically, PPE shows few specific findings. Mild spongiosis, scattered necrotic and dyskeratotic keratinocytes and vacuolar degeneration of the basal layer is seen. Dermal changes in most cases include dilated blood vessels, papillary edema, and a sparse superficial perivascular lymphohistiocytic infiltrate can be found in varying degrees in the epidermis.
Withdrawal or dose reduction of the implicated drug usually gives rise to amelioration of the symptoms. Supportive treatments such as topical wound care, elevation, and cold compresses may help to relieve the pain. Use of systemic corticosteroids, pyridoxine (vitamin B6), blood flow reduction, and, recently, topical 99% dimethyl-sulfoxide have been used with variable outcomes. It could be of interest to consider them as preventive measures when drugs with a strong association with PPE are going to be administered.
Similar content being viewed by others
References
Zuehlke R.K. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974; 148 (2): 90–92
Komamura H., Higashiyama M., Hashimoto K., et al. Three cases of chemotherapy-induced acral erythema. J Dermatol 1995 Feb; 22 (2): 116–121
Amantea M., Newman M.S., Sullivan T.M., et al. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthesia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999 Jan; 18 (1): 17–26
Azurdia R.M., Clark R.E., Friedmann P.S. Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clin Exp Dermatol 1999 Mar; 24 (2): 64–66
Ayash LJ, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol Mar; 16 (3): 1000-1007
Baer M.R., King L.E., Wolff S.N. Palmar-plantar erythrodysesthesia and cytarabine. Ann Intern Med 1985 Apr; 102 (4): 556
Banfield G.K., Crate I.D., Griffiths C.L. Long-term sequelae of palmar-plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. J R Soc Med 1995 Jun; 88 (6): 356P–357P
Bastida J., Diaz-Cascajo C., Borghi S. Chemotherapy-induced acral erythema due to Tegafur. Acta Derm Venereol 1997 Jan; 77 (1): 72–73
Beard J.S., Smith K.J., Skelton H.G. Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versushost disease. J Am Acad Dermatol 1993 Aug; 29 (2 Pt 2): 325–330
Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel refractory metastatic breast cancer. J Clin Oncol 1999 Feb; 17 (2): 485–493
Budd G.T., Fleming T.R., Bukowsky R.M., et al. 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Soutwest Oncology Group study. J Clin Oncol 1987 Feb; 5 (2): 272–277
Budman D.R., Meropol N.J., Reigner B., et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998 May; 16 (5): 1795–1802
Bunnell C.A., Winer E.P. Oral 5-FU analogues in the treatment of Breast Cancer. Oncology (Huntingt) 1998 Oct; 12 (10 Suppl. 7): 39–43
Burgdorf W.H., Gilmore W.A., Ganick R.G. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982 Jul; 97 (1): 61–62
Calista D., Landi C. Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis? J Eur Acad Dermatol Venereol 1998 May; 10 (3): 274–275
Camps C., Soler J.J., Godes M.J., et al. Toxicidad cutánea del ftorafur, síndrome manos- pies o eritrodisestesia palmoplantar. Rev Clin Esp 1991; 188: 165–166
Cassidy J., Dirix L., Bissett D., et al. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998 Nov; 4 (11): 2755–2761
Chiara S., Nobile M.T., Barzacchi C., et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 1997; 33 (6): 967–969
Cohen P.R. Acral erythema: a clinical review. Cutis 1993 Mar; 51 (3): 175–179
Comandone A., Bretti S., LaGrotta G., et al. Palmar-plantar erythrodysesthesia syndrome associated with 5-fluorouracil treatment. Anticancer Res 1993; 13: 1781–1783
Conroy T., Geoffrois L., Guillemin F., et al. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer 1993 Oct 1; 72 (7): 2190–2197
Cordonnier C., Roujeau J.C., Vernant J.P., et al. Cancer Chemotherapy and acral erythema. Ann Intern Med 1982; 97: 783
Cox G.J., Robertson D.B. Toxic erythema of palms and soles associated with highdose mercaptopurine chemotherapy. Arch Dermatol 1986; 122: 1413–1414
Crider M.K., Jansen J., Norins A.L., et al. Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 1986 Sep; 122 (9): 1023–1027
Curran C.F., Luce J.K. Fluorouracil and palmar-plantar erythrodysesthesia. Ann Intern Med 1989 Nov 15; 111 (10): 858
De Argila D., Dominguez J.D., Iglesias L. Taxol-induced acral erythema. Dermatology 1996; 192 (4): 377–378
De Argila Fernández-Durán D., Rivera Díaz R., López Estebaranz J.L., et al. Eritema acral inducido por 5-fluorouracilo en infusión contínua. Presentación de un caso y revisión de la literatura. Actas Dermosifiliogr 1993; 84: 315–318
De Gramont A., Louvet C., André T., et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Eur J Cancer 1998; 34 (5): 619–626
Demircay Z., Gurbuz O., Alpdogan T.B., et al. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol 1997 Aug; 36 (8): 593–598
Díaz-Rubio E, Aranda E., Martín M., et al. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 1990; 26; 727–729
Doyle L.A., Berg C., Bottino G., et al. Erythema and desquamation after high-dose methotrexate. Ann Intern Med 1983; 98: 611–612
Ellerhorst J.A., Bedikian A., Ring S., et al. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep 1999 Sep-Oct; 6 (5): 1097–1099
Fabian C.J., Molina R., Slavik M., et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57–63
Fariña M.C., Andrade J., Soriano M.L., et al. Eritema acral inducido por quimioterapia. Descripción de cuatro casos y revisión de la literatura. Actas Dermosifiliogr 1998; 89: 385–391
Gabizon A., Catane R., Uziely B. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987–992
Gabra H., Cameron D.A., Lee L.E., et al. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. Br J Cancer 1996; 74: 2008–2012
Gordon K.B., Tajuddin A., Guitart J., et al. Hand-foot syndrome associated with liposome- encapsulated doxorubicin therapy. Cancer 1995; 75: 2169–2173
Guillaume J.C., Carp E., Rougier P., et al. Effets secondaires cutanéo-muqueux des perfusions continues de 5-fluorouracile: 12 observations. Ann Dermatol Venereol 1988; 115: 1167–1169
Hellier I., Bessis D., Sotto A., et al. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996 May; 132 (5): 590–591
Herzig R.H., Wolff S.N., Lazarus H.M., et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361–369
Hines J.D., Zakem M.H., Adelstein T.J., et al. Treatment of advanced stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study. J Clin Oncol 1988; 6: 142–146
Hoff P.M., Valero V., Ibrahim N., et al. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998 Mar 1; 82 (5): 965–969
Ikeda H., Kawano H., Kitaura T., et al. Acral erythema associated with high-dose methotrexate infusion. Ann Pharmacother 1999 May; 33 (5): 646
Jucglà A., Sais G., Navarro M., et al. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995 Mar; 131 (3): 364–365
Kampmann K.K., Graves T., Rogers S.D. Acral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusions. Cancer 1989 Jun 15; 63 (12): 2482–2485
Koletsky A., Jahanzeb M., Radice P., et al. A randomized phase II trial of pegylated liposomal doxorubicin (PG-LD) as second line treatment in non-small cell lung cancer (NSCLC) patients with prior exposure to platinum based therapy [abstract 1888]. Proc Am Soc Clin Oncol 1998; 17: 490A
Kroll S.S., Koller C.A., Kaled S., et al. Chemotherapy-induced acral erythema: desquamating lesions involving the hands and feet. Ann Plast Surg 1989 Sep; 23 (3): 263–265
Krulder J.W.M., Vlasveld L.T., Willemze R. Erythema and swelling of ears after treatment with cytarabine for leukemia. Eur J Cancer 1990; 26: 649–650
Leichman C.G., Leichman L., Spears C.P., et al. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 1993; 85: 41–44
Levine L.E., Medenica M.M., Lorincz A.L., et al. Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 1985 Jan; 121 (1): 102–104
Lokich J.J., Ahlgren J.D., Gullo J.J., et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–432
Lokich J.J., Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798–800
Matsuyama J.R., Kwok K.K. A variant of the chemotherapy-associated erythrodysesthesia syndrome related to high-dose cyclophosphamide. DICP 1989 Oct; 23 (10): 776,778-9
Meta-Analysis Group in Cancer Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998 Nov; 16 (11): 3537–3541
Millot F., Auriol F., Brecheteau P., et al. Acral erythema in children receiving highdose methotrexate. Pediatr Dermatol 1999 Sep-Oct; 16 (5): 398–400
Mortimer J.E., Anderson I. Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol 1990; 26: 449–452
Muggia F.M., Hainsworth J.D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractarory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997 Mar; 15 (3): 987–993
Murphy C.P., Harden E.A., Herzig R.H. Dose-related cutaneous toxicities with etoposide. Cancer 1993 May 15; 71 (10): 3153–3155
Nagore E, Sánchez-Motilla J.M., Insa A., et al. Síndrome de eritrodisestesia palmoplantar por 5-fluorouracilo: respuesta favorable al tratamiento con piridoxina. Med Cut I L A 1998; 26: 35–38
Ogawa H., Sugiyama H., Tani Y., et al. High incidence of chemotherapy-induced acral erythema in female patients with non-Hodgkin’s lymphoma treated with the VACOP-B regimen. Leuk Lymphoma 1998 Mar; 29 (1–2): 171–177
Peters W.G., Willemze R. Palmar-plantar skin changes and cytarabine. Ann Intern Med 1985; 103: 805
Popescu R.A., Norman A., Ross P.J., et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999 Aug; 17 (8): 2412–2418
Portal I., Cardenal F., Garcia-del-Muro X. Etoposide-related acral erythema. Cancer Chemother Pharmacol 1994; 34 (2): 181
Revenga Arranz F., Fernandez-Duran D.A., Grande C., et al. Acute and painful erythema of the hands and feet. Acral erythema induced by chemotherapy. Arch Dermatol 1997 Apr; 133 (4): 499–500, 502-3
Rios-Buceta L, Buezo G.F., Peñas P.F., et al. Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur. Acta Derm Venereol 1997 Jan; 77 (1): 80–81
Rongioletti F., Ballestrero A., Bogliolo F., et al. Necrotizing eccrine squamous syringometaplasia presenting as acral erythema. J Cutan Pathol 1991 Dec; 18 (6): 453–456
Samuels B.L., Vogelzang N.J., Ruane M., et al. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 1987 Oct; 71 (10): 971–972
Schuster D., Heim M.E., Decoster G., et al. Phase I–II trial of doxifluridine (5’DFUR) administered as long-term continuous infusion using a portable infusion pump for advanced colorectal cancer. Eur J Cancer Clin Oncol 1989 Nov; 25 (11): 1543–1548
Sella A., Kilbourn R., Amato R., et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 1994 Apr; 12 (4): 683–688
Shall L., Lucas G.S., Whittaker J.A., et al. Painful red hands: a side effect of leukaemia therapy. Br J Dermatol 1988; 119: 249–253
Silver F.S., Espinoza L.R., Hartmann R.C. Acral erythema and hydroxyurea. Ann Intern Med 1983 May; 98 (5 Pt 1): 675
Uziely B., Jeffers S., Isacson R., et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995 Jul; 13 (7): 1777–1785
Vakalis D., Ioannides D., Lazaridou E., et al. Acral erythema induced by chemotherapy with cisplatin. Br J Dermatol 1998 Oct; 139 (4): 750–751
Vargas-Diez E., Abajo P., Fraga J., et al. Chemotherapy-induced acral erythema. Acta Derm Venereol 1999 Mar; 79 (2): 173–175
Villalona-Calero M.A., Weiss G.R., Burris H.A., et al. Phase I and pharmacokynetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 1999 Jun; 17 (6): 1915–1925
Waltzer J.F., Flowers F.P. Bullous variant of chemotherapy-induced acral erythema. Arch Dermatol 1993 Jan; 129 (1): 43–45
Weh H.J., Wilke H.J., Dierlamm J., et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5: 233–237
Whitlock J.A., Wells R.J., Hord J.D., et al. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia. Leukemia 1997 Feb; 11 (2): 185–189
Zimmerman G.C., Keeling J.H., Burris H.A., et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995 Feb; 131 (2): 202–206
Perry M.C., editor. The chemotherapy source book. 2nd ed. Baltimore, USA: Williams & Wilkins, 1996
Vukelja S.J., Lombardo F.A., James W.D., et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989 Oct 15; 111 (8): 688–689
Brown J., Burck K., Black D., et al. Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 1991 Jun; 24 (6 Pt 1): 1023–1025
Titgan M.A. Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil®) by oral dexamethasone [abstract 288]. Proc Am Soc Clin Oncol 16: 82A, 1997
Vail D.M., Chun R., Thamm D.H., et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998 Jun; 4 (6): 1567–1571
Lopez A.M., Wallace L., Dorr R.T., et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999; 44 (4): 303–306
Vukelja S.J., Baker W.J., Burris III H.A. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993 Sep 1; 85 (17): 1432–1433
Zimmerman G.C., Keeling J.H., Lowry M., et al. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst 1994; 86: 557
Susser W.S., Whitaker-Worth D.L., Grant-Kels J.M. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40: 367–398
Baack B.R., Burgdorf W.H. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991 Mar; 24 (3): 457–461
Valks R., Fraga J., Porras-Luque J., et al. Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol 1997; 133: 873–878
Esteve E., Schillio Y., Vaillant L., et al. Efficacité de la corticothérapie séquentielle dans un cas d’érythème acral douloureux secondaire au 5-fluoro-uracile à fortes doses. Ann Med Interne (Paris) 1995; 146 (3): 192–193
Fitzpatrick J.E. The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol. 1993 Feb; 20 (1): 1–14
Sanmartín O., Botella R., Guill én C. Efectos adversos cutáneous de la quimioterapia. Piel 1996 Oct; 11 (8): 406–418
Sale G.E., Lerner K.G., Barker E.A., et al. The skin biopsy in the diagnosis of acute graft-versus-host disease of man. Am J Pathol 1977; 89: 621–635
Van Cutsem E., Findlay M., Osterwalder B., et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000 Mar; 18 (6): 1337–1345
Burnstain H.J., Manola J., Younger J., et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000 Mar; 18 (6): 1212–1219
Becker K.W., Kienecker E.W., Dick P. A contribution to the scientific assessment of degenerative and regenerative processes of peripheral nerve fibers following axonotmesis under the systemic administration of vitamins B1, B6 and B12—light and electron microscopy findings of the saphenous nerve in the rabbit. Neurochirurgia (Stuttg) 1990 Jul; 33 (4): 113–121
Shah B.R., Santucci K., Sinert R., et al. Acute isoniazid neurotoxicity in an urban hospital. Pediatrics 1995 May; 95 (5): 700–704
Nand S., Messmore Jr H.L., Patel R., et al. Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol 1986 Apr; 4 (4): 571–575
Jackson Jr D.V., Pope E.K., McMahan R.A., et al. Clinical trial of pyridoxine to reduce vincristine neurotoxicity. J Neurooncol 1986; 4 (1): 37–41
Wiernik P.H., Yeap B., Vogl S.E., et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992; 10 (1): 1–9
Bertelli G., Gozza A., Forno G.B., et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995 Nov; 13 (11): 2851–2855
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nagore, E., Insa, A. & Sanmartín, O. Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome. Am J Clin Dermatol 1, 225–234 (2000). https://doi.org/10.2165/00128071-200001040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200001040-00004